Aomo Announces China's NMPA Acceptance of NDA for Adamgammadex

HANGZHOU, China, September 18, 2024, Aomo Pharma, Inc. (the US branch of Adamerck) announced today that the China National Medical Products Administration (NMPA) accepted its new drug application (NDA) for Adamgammadex (Aom0498).

Adamgammadex (Aom0498) is the next generation of specific neuromuscular blockade antagonists and has been shown to rapidly reverse neuromuscular blockades induced by rocuronium at various depths within 3 minutes. Compared with sugammadex, adamgammadexhas a lower incidence of severe adverse reactions, such as allergic reactions, neuromuscular blockade recurrence, bradycardia, and laryngospasm, while maintaining more stable efficacy.

Adamgammadex has been developed globally; it has completed an End of Phase II Meeting with the FDA, and multiregional clinical trials (MRCTs) are scheduled to be launched in the US, Europe, and Japan to bring adamgammadex (Aom0498) into the global market.